Seminars in Hematology
Volume 45 , Pages S7-S11 , April 2008

Further Understanding of Recombinant Activated Factor VII Mode of Action

  • Dougald M. Monroe

      Affiliations

    • Corresponding Author InformationAddress correspondence to Dougald M. Monroe, PhD, Division of Hematology/Oncology, 932 Mary Ellen Jones Building, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7035.

References 

  1. Hedner U. Recombinant factor VIIa: Its background, development and clinical use. Curr Opin Hematol. 2007;14:225–229
  2. Diness V, Lund-Hansen T, Hedner U. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. Thromb Res. 1990;59:921–929
  3. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis. 1996;26(suppl 1):159–164
  4. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol. 2006;124:747–757
  5. Kempton CL, Harvey RD, Roberts HR. Novel therapeutic agents in the management of hemorrhage and thrombosis. Cardiovasc Hematol Agents Med Chem. 2006;4:319–334
  6. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22:1381–1389
  7. Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost. 2007;5:1403–1408
  8. Sixma JJ, van den Berg A. The haemostatic plug in haemophilia A: A morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol. 1984;58:741–753
  9. Dale GL. Coated-platelets: An emerging component of the procoagulant response. J Thromb Haemost. 2005;3:2185–2192
  10. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood. 2003;101:1864–1870
  11. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542–547
  12. Kjalke M, Kjellev S, Rojkjaer R. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J Thromb Haemost. 2007;5:774–780
  13. Allen GA, Hoffman M, Roberts HR, Monroe DM. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. Br J Haematol. 2006;134:314–319
  14. Butenas S, Brummel KE, Bouchard BA, Mann KG. How factor VIIa works in hemophilia. J Thromb Haemost. 2003;1:1158–1160
  15. Sørensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol. 2007;137:158–165
  16. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol. 2005;131:645–655
  17. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80:773–778
  18. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G, et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors (A multi-centre, randomised, double-blind, cross-over trial). Thromb Haemost. 2006;95:600–605
  19. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2:899–909
  20. Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004;57:709–719
  21. Haan J, Scalea T. A Jehovah's Witness with complex abdominal trauma and coagulopathy: Use of factor VII and a review of the literature. Am Surg. 2005;71:414–415
  22. Karkouti K, Beattie WS, Crowther MA, Callum JL, Chun R, Fremes SE, et al. The role of recombinant factor VIIa in on-pump cardiac surgery: Proceedings of the Canadian Consensus Conference. Can J Anaesth. 2007;54:573–582
  23. Poon M, D'Oiron R, Von Depka M, Khair K, Négrier C, Karafoulidou A, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: Results of an international survey. J Thromb Haemost. 2004;2:1096–1103
  24. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery. 2003;53:34–39
  25. Tobias JD. Synthetic factor VIIa to treat dilutional coagulopathy during posterior spinal fusion in two children. Anesthesiology. 2002;96:1522–1525
  26. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293–298
  27. Gabriel DA, Li X, Monroe DM, Roberts HR. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost. 2004;2:1816–1822
  28. Wielders SJ, Béguin S, Hemker HC, Lindhout T. Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available. Arterioscler Thromb Vasc Biol. 2004;24:1138–1142
  29. Wegert W, Harder S, Bassus S, Kirchmaier CM. Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant factor VIIa. Platelets. 2005;16:45–50
  30. Gerotziafas GT, Chakroun T, Depasse F, Arzoglou P, Samama MM, Elalamy I. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost. 2004;91:977–985
  31. Galán AM, Tonda R, Pino M, Reverter JC, Ordinas A, Escolar G. Increased local procoagulant action: A mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion. 2003;43:885–892
  32. Lisman T, Adelmeijer J, Cauwenberghs S, Van Pampus ECM, Heemskerk JW, De Groot PG. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost. 2005;3:742–751
  33. Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis. 2007;18:547–553
  34. Sørensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost. 2003;1:551–558
  35. Stuckey A, Ezban M, Hedner U, Hoffman M, Roberts HR, Monroe DM. High dose factor VIIa corrects thrombin generation in a model of dilutional coagulopathy. J Thromb Haemost. 2007;5(suppl 2):P-S-081

 STATEMENT OF CONFLICT OF INTEREST: Dougald Monroe has a University of North Carolina-administered research grant funded by Novo Nordisk. He has also received honoraria from Novo Nordisk for speaking at meetings.

PII: S0037-1963(08)00053-X

doi: 10.1053/j.seminhematol.2008.03.013

Seminars in Hematology
Volume 45 , Pages S7-S11 , April 2008

Article Tools

* Image Usage & Resolution